Quarterly Earnings

NKT A/S posts record earnings and a €10B backlog, launching a new strategy and major investments to dominate the booming power cable market.

The professional information giant posted robust 2025 earnings while ramping up AI investment and navigating a pivotal CEO transition. Here's what it means.

With its transformative Lanteris acquisition complete, all eyes are on Intuitive Machines' upcoming financial results for clues to its future as a space prime.

The healthcare specialist reported a staggering 2025 net loss due to a write-down, but projects 30% revenue growth fueled by new contracts.

Amid private credit turmoil, SLR Investment Corp. posts solid 2025 results, leveraging a strategic pivot to asset-based lending for stability and returns.

AI marketing firm Zeta Global smashes records for the 18th straight quarter, raising guidance and projecting its first full year of GAAP profitability.

Fueled by policy incentives and strong demand, First Solar reports robust 2025 growth and accelerates its US factory expansion, cementing its market leadership.

Latin American giant MercadoLibre posts record revenue for 2025 but misses profit estimates, sending shares lower as it invests heavily in future growth.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

With 43% YoY growth, Cato Networks is outpacing the SASE market. A new acquisition and key hires signal a deep focus on securing the AI era.

Intellia Therapeutics prepares for a critical March, where it will outline its gene editing future to investors amid safety questions and market pressures.

The bioprocessing leader posted robust 2025 earnings, outperforming the market with strategic innovation and a major expansion into Asian markets.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

The powertrain giant crushed market expectations with a 29% revenue surge in 2025, fueled by heavy-duty engines, while eyeing a global and green future.

The cannabis giant upsizes its credit facility by CAD $15M, signaling strong lender confidence and fueling its ambitious global expansion plans.

Beam Therapeutics is set to announce its 2025 financial results and a new liver-targeted therapy, a key moment for its base editing platform and investors.

With promising data in cancer and eczema, all eyes are on Corvus Pharmaceuticals as it presents its lead drug at a major healthcare conference this week.

Primoris Services Corp. posted a record $7.6B revenue for 2025, but a Q4 profit dip and project hurdles hint at challenges in its booming renewables arm.

With a new CEO and a key investor conference ahead, Metagenomi bets on its unique metagenomics platform and a hemophilia drug to navigate a tough market.

The company's revenue skyrocketed, but SEC filings reveal a story of significant liquidity risks and a bold gamble on the booming wellness market.